This isn’t funding recommendation. The writer has no place in any of the shares talked about. WCCF TECH INC has a disclosure and ethics coverage.
Novo Nordisk (NYSE: NVO) has added billions of {dollars} in market capitalization over the continued craze across the GLP-1 anti-obesity and anti-diabetes medicine. Nevertheless, the Danish pharma large’s most recognizable weight reduction drug, Wegovy, is more and more wanting like a stepping stone as a substitute of the promised panacea for the weight problems pandemic.
For the good thing about those that may not remember, the GLP-1 hormone performs an necessary position in suppressing starvation and regulating the manufacturing of insulin and glucose. After a meal, GLP-1 agonists elevate the extent of insulin, which decreases blood glucose ranges. Concurrently, these medicine scale back the pace at which the abdomen empties its contents into the small gut, thereby rising the sensation of fullness and satiation. Novo Nordisk makes use of Semaglutide as its proprietary GLP-1 agonist in medicine which might be marketed below Ozempic and Wegovy labels, with the previous geared towards type-2 diabetes and the latter marketed as a remedy for weight problems.
Whereas Novo Nordisk at present has plenty of further GLP-1 medicine within the pipeline, together with these that may be ingested and those who leverage each GLP-1 and Amylin agonists to supply higher efficacy, Wegovy and Ozempic stay the corporate’s main GLP-1 choices for now. But, these medicine are more and more besieged by considerations round efficacy, pricing, and negative effects.
The Month-to-month Dose of Novo Nordisk’s Ozempic and Wegovy GLP-1 Drug Prices Simply Round $5, But It Retails for $1,300 within the US With out Any Insurance coverage Protection
A brand new research printed within the JAMA Open Community towards the top of March has concluded {that a} month-to-month dose of Novo Nordisk’s Ozempic and Wegovy medicine entails manufacturing prices of simply round $5. Nevertheless, Ozempic’s month-to-month dose is at present being offered within the US at $935.77 for these with none medical insurance coverage protection, with Wegovy commanding an excellent increased price ticket at round $1,300 per 30 days (sans insurance coverage).
See extra
There isn’t a rational purpose, apart from greed, for Novo Nordisk to cost Individuals practically $1,000 a month for Ozempic when it prices lower than $5 to fabricate it and may be bought in Germany for simply $59. Novo should considerably scale back the worth of Ozempic within the US now. pic.twitter.com/rdyF5MCQbX
— Bernie Sanders (@SenSanders) March 27, 2024
This discrepancy is all of the extra putting when one considers the truth that Ozempic is being offered in Germany for simply round $59 per 30 days. Granted, FDA approvals within the US normally entail elevated prices that may run into thousands and thousands and even a whole lot of thousands and thousands of {dollars}. And, in fact, Novo Nordisk is entitled to attempt to recoup its R&D bills on the drug. Even so, the size of this pricing discrepancy has all of the traits of morphing into an argument.
Pharmaceutical Corporations Now Face Dozens of Lawsuits After Some Individuals Suffered From Severe Aspect Results Associated to GLP-1 Medicine
See extra
DOZENS SUE SAYING OZEMPIC, OTHER WEIGHT LOSS AND DIABETES DRUGS CAUSE HARMFUL SIDE EFFECTS (USA As we speak)
Paulsen Bronston tried completely different drugs to handle his diabetes, to no avail, earlier than his physician urged a brand new drug.
In 2018, the physician suggested Bronston, who lives in… pic.twitter.com/xxuBkYyfff
— FXHedge (@Fxhedgers) March 23, 2024
GLP-1 medicine from the likes of Novo Nordisk and Eli Lilly and Firm do entail widespread negative effects, together with nausea, vomiting, and diarrhea. Nevertheless, a couple of folks have reportedly encountered far more severe negative effects, starting from “insufferable ache” to gallbladder dysfunction.
Pharmaceutical corporations now face over 5 dozen lawsuits associated to the negative effects induced by their GLP-1 choices. Novo Nordisk, nevertheless, faces the biggest variety of lawsuits on this cohort.
Novo Nordisk’s Wegovy May Not be as Efficient at Weight Loss as Beforehand Believed
See extra
$NVO $LLY | In line with the WSJ, NOT everybody taking Ozempic & Wegovy sees weight reduction—as much as 15% of customers have little to NO change as a consequence of genetics and different elements.
Docs discover a variety in outcomes with GLP-1 medicine, figuring out about 10% to fifteen% as “non-responders,”… pic.twitter.com/kzIZRefkhJ
— Wall St Engine (@wallstengine) April 1, 2024
Wall Road Journal just lately quoted medical doctors to report that between 10 and 15 % of Wegovy customers don’t expertise any materials weight reduction from this drug, owing to genetics, current medical situations, and prior weight reduction strategies that have been leveraged by these customers.
Apparently, the share of non-responders is far decrease for Eli Lilly and Firm’s Mounjaro GLP-1 providing. This once more harkens to our authentic thesis that Novo Nordisk’s Wegovy shouldn’t be an anti-obesity panacea.